1、novotech-NOVEMBER 30,2023HIV Global ClinicalTrial LandscapeAPAC,led by China and India,accounted for 29%of HIV trialsSpain,France in Europe,and the US in North America take the leadSouth Africa led among other regions with 31%of HIV trialsAPAC show-cased quicker recruitment durations and faster pati

2、ent recruitment ratesNorth America led with the highest CAGR growth,while APAC displayed steady growth31%29%HIV,transmitted via bodily fluids com-promises the immune system,increasing vulnerability to infections and AIDS.Novagen Pharma,Pharma Dynamics,and Cipla Medpro focus on ART treatment in South

3、 Africa while Aurobindo Pharma USA innovates in the USViiV Healthcare UK Ltd introduced new medication combos such as CAB-LAUpcoming phase III trials embrace gene editing techniques,antibodies,and vaccines,indicating a broader approach to combat HIVDidyouknow?Globally,39 million individuals were liv

4、ing with HIV in 2022In 2022,there were 1.3 million new global HIV infectionsUNICEF predicts the HIV epidemic among adolescents and young people to persist until 2050 globallyHIV remains a significant global concern,claiming 40.4 million lives to dateAt the regional level,Eastern and Southern Africa

5、were mostly afectedAt the national level,South Africa,and India were heavily afectedThe content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recording,or othe

6、r electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other materials o